Full-year 2025 worldwide sales were $94.2 billion, up 5.3% operationally despite an approximate 620 basis point headwind from Stelara. U.S. growth was 6.9% and growth outside the U.S. was 3.4%. Acquisitions and divestitures contributed 110 basis points, driven primarily by the Intra-Cellular and Shockwave acquisitions.For the quarter, net earnings were $5.1 billion and diluted EPS was $2.10 versus $1.41 a year earlier. Adjusted net earnings were $6.0 billion and adjusted diluted EPS was $2.46, representing ...

Core Insights - Globus Medical, Inc. (NYSE:GMED) is a leading medical device company focused on healthcare solutions in the musculoskeletal sector, known for its innovative products and strong emphasis on research and development [1] Performance Summary - Over the past month, GMED has gained approximately 4.71%, indicating strong upward momentum in a volatile healthcare sector [2] - Despite a slight dip of 0.36% in the last 10 days, this presents a potential buying opportunity as the stock approaches a local minimum, suggesting a possible rebound [2] Growth Potential - GMED has an estimated upside of 5.16%, indicating significant growth potential and making it an attractive option for investors seeking growth opportunities in the healthcare sector [3] Financial Health - The company boasts a robust Piotroski Score of 8, reflecting a strong financial position and the ability to generate profits and manage financial resources effectively [4] - Analysts have set a target price of $97.75 for GMED, which aligns with its growth potential and reflects confidence in the stock's ability to reach this level [5][6]

Looking for more investing ideas like this one? Get them exclusively at The Dividend Kings. Learn more >>Blending quality and value can be a particularly effective investing strategy. But what do I mean by "quality" and what do I mean by "value?"Hi, my name is Kody. Aside from my articles here on Seeking Alpha, I am also a regular contributor to Sure Dividend, The Dividend Kings, and iREIT+Hoya Capital. I have been investing since September 2017 (age 20) and interested in dividend investing since about 2009 ...

Johnson & Johnson (JNJ) stock tumbled Wednesday, though the company issued strong 2026 guidance, as Boston Scientific (BSX) and Medtronic (MDT) continue undercutting its electrophysiology business. Electrophysiology tools study the heart's rhythm. Pulsed field ablation, or PFA, is an electrophysiology tool that uses high-voltage electrical pulses to destroy problematic heart tissue, thus restoring normal rhythm for people with atrial fibrillation.… ...

Avalon GloboCare Corp (NASDAQ:ALBT) stock is trading lower on Wednesday. Apparently, there is no news to justify the movement.Avalon GloboCare, a company for precision diagnostic consumer products, on Tuesday announced the renewal of the U.S. Food and Drug Administration (FDA) establishment registration for its KetoAir device, a handheld breathalyzer designed for ketogenic health management.The device measures breath acetone concentration (BrAce), a key biomarker associated with fat metabolism and nutrition ...

Key Takeaways Intuitive Surgical's narrow robotics strategy drives coordinated da Vinci 5 rollouts and rising utilization.ISRG generates 85% of revenues from recurring sources, translating 19% procedure growth into expansion.MDT faces tariff headwinds, uneven procedure recovery and distributor shifts, weighing near-term margins.Intuitive Surgical (ISRG) and Medtronic (MDT) represent two very different approaches to scale in MedTech. Intuitive Surgical is a focused, pure-play leader in robotic-assisted surge ...

Key Takeaways HOLX's GYN Surgical revenues rose 10.2% to $172.5M last quarter, led by MyoSure, Fluent and Gynesonics.HOLX's Surgical outlook is supported by forecast 8.8% revenue growth versus last year, per consensus.Hologic sees adoption outside the U.S. rise as new reimbursement lifts NovaSure and MyoSure growth.Hologic’s (HOLX) GYN Surgical business is benefiting from a mix of internal innovation and product line additions through M&A, positioning it as a meaningful growth driver. The portfolio includes ...

Key Takeaways IDXX's Q3 CAG Diagnostics recurring revenues grew over 10% organically due to U.S. and overseas gains.IDEXX expands globally with strong installed base growth and plans to enter three new countries by 2026.IDEXX faces liquidity risks and a stronger dollar, trimming margins on international sales.IDEXX Laboratories, Inc. (IDXX) is well-poised to grow in the upcoming quarters due to the strong momentum in its CAG (Companion Animal Group) Diagnostics business. The company is also growing its glob ...

RA'ANANA, Israel, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today provided an update highlighting significant progress in the execution of its previously announced binding purchase orders. The Company has received a formal notification from its distribution partner that the $22.5 million and $27 million binding purchase orders, originally announced on July 2, 202 ...

PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”) on behalf of investors who purchased or otherwise acquired Integer securities during the period of July 25, 2024 through October 22, 2025 (the “Class Period”), inclusive. Investor Deadline: Investors who purchased Integer securities during the Class Period may, no later than Februar ...